Abstract
Sodium benzoate has been used for the treatment of congenital hyperammonemic syndromes and hepatic encephalopathy for its ammonia lowering effect. A zinc-derivative of sodium benzoate (CH-1) with similar effects, is presented herein. We administered CH-1 at doses of 250, 500 and 1000 mg/kg body weight during 7 days to male Wistar rats after a portocaval shunt operation was performed as a model for experimental hyperammonemia. There was a decrease in blood ammonia levels in all groups receiving CH-1. A linear relationship (r=-0.487, P < 0.01) was observed between the dose of CH-1 and blood ammonia levels. The effective dose 50 (ED50) was 320 mg/kg body weight (95% C.I. 176-581 mg) with a slope of 1.538 (Litchfield and Wilcoxon method). These results suggest that benzoic acid salts such as CH-1 may prove a new alternative for the treatment of hyperammonemia. Potential advantages of non-sodium salts of benzoic acid are discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 104-109 |
| Number of pages | 6 |
| Journal | Hepatology Research |
| Volume | 15 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jul 1999 |
| Externally published | Yes |
Fingerprint
Keywords
- Hepatic encephalopathy
- Hyperammonemia
- Pharmacology
- Sodium benzoate
- Treatment
- Zinc
ASJC Scopus subject areas
- Gastroenterology
Cite this
A novel sodium benzoate analog (CH-1) decreases blood ammonia levels in experimental hyperammonemia. / Campollo, Octavio; Cortez, Ruben; Odor, Alberto M; Maria Muñoz, Rosa; Armendariz-Borunda, Juan; Alvarez-Tostado, Javier.
In: Hepatology Research, Vol. 15, No. 2, 07.1999, p. 104-109.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A novel sodium benzoate analog (CH-1) decreases blood ammonia levels in experimental hyperammonemia
AU - Campollo, Octavio
AU - Cortez, Ruben
AU - Odor, Alberto M
AU - Maria Muñoz, Rosa
AU - Armendariz-Borunda, Juan
AU - Alvarez-Tostado, Javier
PY - 1999/7
Y1 - 1999/7
N2 - Sodium benzoate has been used for the treatment of congenital hyperammonemic syndromes and hepatic encephalopathy for its ammonia lowering effect. A zinc-derivative of sodium benzoate (CH-1) with similar effects, is presented herein. We administered CH-1 at doses of 250, 500 and 1000 mg/kg body weight during 7 days to male Wistar rats after a portocaval shunt operation was performed as a model for experimental hyperammonemia. There was a decrease in blood ammonia levels in all groups receiving CH-1. A linear relationship (r=-0.487, P < 0.01) was observed between the dose of CH-1 and blood ammonia levels. The effective dose 50 (ED50) was 320 mg/kg body weight (95% C.I. 176-581 mg) with a slope of 1.538 (Litchfield and Wilcoxon method). These results suggest that benzoic acid salts such as CH-1 may prove a new alternative for the treatment of hyperammonemia. Potential advantages of non-sodium salts of benzoic acid are discussed.
AB - Sodium benzoate has been used for the treatment of congenital hyperammonemic syndromes and hepatic encephalopathy for its ammonia lowering effect. A zinc-derivative of sodium benzoate (CH-1) with similar effects, is presented herein. We administered CH-1 at doses of 250, 500 and 1000 mg/kg body weight during 7 days to male Wistar rats after a portocaval shunt operation was performed as a model for experimental hyperammonemia. There was a decrease in blood ammonia levels in all groups receiving CH-1. A linear relationship (r=-0.487, P < 0.01) was observed between the dose of CH-1 and blood ammonia levels. The effective dose 50 (ED50) was 320 mg/kg body weight (95% C.I. 176-581 mg) with a slope of 1.538 (Litchfield and Wilcoxon method). These results suggest that benzoic acid salts such as CH-1 may prove a new alternative for the treatment of hyperammonemia. Potential advantages of non-sodium salts of benzoic acid are discussed.
KW - Hepatic encephalopathy
KW - Hyperammonemia
KW - Pharmacology
KW - Sodium benzoate
KW - Treatment
KW - Zinc
UR - http://www.scopus.com/inward/record.url?scp=0032818053&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032818053&partnerID=8YFLogxK
U2 - 10.1016/S1386-6346(99)00016-9
DO - 10.1016/S1386-6346(99)00016-9
M3 - Article
AN - SCOPUS:0032818053
VL - 15
SP - 104
EP - 109
JO - International Hepatology Communications
JF - International Hepatology Communications
SN - 0928-4346
IS - 2
ER -